1207516-29-7

Upstream product

• 1207516-28-6 ethyl 10-fluoro-6-(3-fluoro-4-methoxybenzyl)-1,2,4,7-tetrahydro-3H-indolo[2,3-c][1,7]naphthyridine-3-carboxylate 

Downstream Products

• 1207516-35-5 1-[10-fluoro-6-(3-fluoro-4-methoxybenzyl)-1,2,4,7-tetrahydro-3H-indolo[2,3-c][1,7]naphthyridin-3-yl]-3-hydroxypropan-1-one 
• 1207516-38-8 2-[10-fluoro-6-(3-fluoro-4-methoxybenzyl)-1,2,4,7-tetrahydro-3H-indolo[2,3-c][1,7]naphthyridin-3-yl]ethanol 
• 1207516-37-7 2-[10-fluoro-6-(3-fluoro-4-methoxybenzyl)-1,2,4,7-tetrahydro-3H-indolo[2,3-c][1,7]naphthyridin-3-yl]acetamide 
• 1207516-52-6 2-[2-(benzyloxy)ethoxy]-1-[10-fluoro-6-(3-fluoro-4-methoxybenzyl)-1,2,4,7-tetrahydro-3H-indolo[2,3-c][1,7]naphthyridin-3-yl]ethanone 
• 1207516-30-0 1-[10-fluoro-6-(3-fluoro-4-methoxybenzyl)-1,2,4,7-tetrahydro-3H-indolo[2,3-c][1,7]naphthyridin-3-yl]ethanone 

Relevant academic research and scientific papers

BENZYL-SUBSTITUTED TETRACYCLIC HETEROCYCLIC COMPOUNDS AS PDE5 INHIBITORS

The present invention pertains to Benzyl-substituted tetracyclic heterocyclic compounds, as well as the resulting pharmaceutical compositions, and their use in the treatment or prophylaxis of diseases alleviated by inhibition of type 5 phosphodiesterases. Furthermore, the present invention pertains to the methods of manufacturing these Benzyl-substituted tetracyclic heterocyclic compounds.